<div id="readability-page-1">Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for Carvykti, its cancer treatment that it is commercializing with Johnson &amp; Johnson’s (JNJ.US) Janssen unit. The vast majority of Legend’s revenue for the quarter, about $298 million, came from its Janssen collaboration, which currently sells Carvykti in 18 global markets, including recent launches in Poland, the Czech Republic and Australia. Total Carvykti sales during the quarter grew 62% year-on-year to $597 million. Legend recorded a net loss of $54.3 million in the latest quarter, narrowing by nearly half from a $101 million loss a year earlier. Its adjusted loss for the quarter narrowed by more than half to $10.5 million from $27 million a year earlier. Legend Biotech’s New York-listed stock rose 10.5% on Tuesday after the results were published. The stock is up 31% year-to-date. By Doug Young To subscribe to Bamboo Works weekly free newsletter, click here</div>

傳奇生物

IBBQ

動態生物技術與基因組 ETF - Invesco

生物科技公司 Legend Biotech 週二報告稱，第一季度收入同比增長 56%，達到 3.051 億美元，受益於與強生旗下的 Janssen 單位合作的癌症治療藥物 Carvykti 的強勁銷售。該季度 Legend 的收入大部分來自與 Janssen 的合作，約為 2.98 億美元。Carvykti 的總銷售額同比增長 62%，達到 5.97 億美元。儘管如此，Legend 在最新季度錄得淨虧損 5430 萬美元，虧損幅度縮小近一半。

BambooWorks

Invesco Nasdaq Biotechnology ETF

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

基因改革 ETF - ARK

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

強生

BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment